A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma.

Trial Profile

A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Dasatinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 19 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top